Fundraising Fox

Araris Biotech

Basel, CH · 6 known investors

Araris develops proprietary antibody-drug conjugate (ADC) linker technology that enables one-step attachment of payloads to native antibodies for targeted cancer therapy. The platform generates stable, homogenous ADCs for oncology applications without requiring antibody re-engineering.

BiotechMedical Devices

Founders & leadership

DGDragan Grabulovski
Dragan Grabulovskiin𝕏Co-founder and CEOVenture Partner at Pureos Bioventures
PSPhilipp Spycher
Philipp SpycherCo-founder and Chief Scientific Officer
IAIsabella Attinger-Toller
Isabella Attinger-TollerCo-founder

Investors · 6

Pureos Bioventures✓ verifiedPfäffikon
redalpine✓ verifiedZug · $108K – $2.2M
Samsung Ventures✓ verifiedMenlo Park
VI Partners✓ verifiedAltendorf · $2.2M – $4.5M
b2ventureBerlin · $270K – $5.4M
Kinled HoldingHong Kongvia Patrick Aisher · inferred

Frequently asked questions

What does Araris Biotech do?
Araris develops proprietary antibody-drug conjugate (ADC) linker technology that enables one-step attachment of payloads to native antibodies for targeted cancer therapy. The platform generates stable, homogenous ADCs for oncology applications without requiring antibody re-engineering.
Who founded Araris Biotech?
Araris Biotech was founded by Dragan Grabulovski, Philipp Spycher, Isabella Attinger-Toller.
Who are Araris Biotech's investors?
Araris Biotech's investors include Pureos Bioventures, redalpine, Samsung Ventures, VI Partners, b2venture, Kinled Holding.
Where is Araris Biotech headquartered?
Araris Biotech is headquartered in Basel, CH.